Global Argatroban

Argatroban Comprehensive Study by Type (Argatroban Powder, Argatroban Injection), Application (Heparin-induced Thrombocytopenia (HIT), Percutaneous Coronary Intervention, Cerebral Arterial Thrombosis, Others), End-Use (Hospitals, Home Care Centres, Pharmacies, Others) Players and Region - Global Market Outlook to 2026

Argatroban Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Argatroban Market Overview:
Argatroban is a crystalline powder that is odorless and freely soluble in glacial acetic acid. Argatroban, an anticoagulant, is a direct thrombin inhibitor that has been licensed by the FDA for prophylaxis or thrombosis in patients with heparin-induced thrombocytopenia (HIT). Adult patients with or at risk of HIT who are undergoing percutaneous coronary intervention should get Argatroban Injection (PCI). Heparin is a more regularly used thrombin inhibitor, although it can cause a platelet count shortage in some people. This has increased the demand for a heparin substitute. Argatroban meets this need by working as a thrombin inhibitor that does not cause heparin-like side effects. Because of the rising incidence of heparin-related problems and the growth in the number of cerebral arterial thrombosis, the argatroban market is expected to develop throughout the near future.

Growth Drivers
  • Increase in the Number of Heparin-Related Complications
  • Rise in Incidence of Percutaneous Coronary Intervention Procedures

Roadblocks
  • Rising Allergies Associated with Argatroban

Opportunities
  • Growing Research and Development Activities


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Pfizer, Inc (United States), Caplin Point Laboratories Ltd (India), Novartis (Switzerland), GlaxoSmithKline Plc (United Kingdom), Fresenius-Kabi (Germany), Eagle Pharmaceuticals, Inc (United States), Mitsubishi Tanabe Pharma (Japan), Teva Pharmaceutical Industries Ltd (Israel), WEST-WARD,INC (United States), Midas Pharma GmBH (Germany) and Aurobindo Pharma Limited (India). Analyst at AMA Research see European Players to retain maximum share of Global Argatroban market by 2026. Considering Market by End-Use, the sub-segment i.e. Hospitals will boost the Argatroban market.

January 2020 – Caplin Point Laboratories announced that its subsidiary, Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Argatroban Injection, 50 mg/50 ml (1 mg/ml) Single-dose vial presentation, a generic therapeutic equivalent version of (RLD), ARGATROBAN INJECTION, of Hikma Pharmaceuticals.

What Can be Explored with the Argatroban Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Argatroban Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Argatroban
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Argatroban market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Argatroban market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Argatroban, Suppliers of Argatroban, Hospitals, Pharmaceutical Companies, Investors and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Argatroban Powder
  • Argatroban Injection
By Application
  • Heparin-induced Thrombocytopenia (HIT)
  • Percutaneous Coronary Intervention
  • Cerebral Arterial Thrombosis
  • Others
By End-Use
  • Hospitals
  • Home Care Centres
  • Pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Spain
    • Rest of Europe
  • MEA
    • Saudi Arabia
    • Turkey
    • Israel
    • United Arab Emirates
    • South Africa
    • Rest of Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Number of Heparin-Related Complications
      • 3.2.2. Rise in Incidence of Percutaneous Coronary Intervention Procedures
    • 3.3. Market Trends
      • 3.3.1. Rising Incidence of Cerebral Arterial Thrombosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Argatroban, by Type, Application, End-Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Argatroban (Value)
      • 5.2.1. Global Argatroban by: Type (Value)
        • 5.2.1.1. Argatroban Powder
        • 5.2.1.2. Argatroban Injection
      • 5.2.2. Global Argatroban by: Application (Value)
        • 5.2.2.1. Heparin-induced Thrombocytopenia (HIT)
        • 5.2.2.2. Percutaneous Coronary Intervention
        • 5.2.2.3. Cerebral Arterial Thrombosis
        • 5.2.2.4. Others
      • 5.2.3. Global Argatroban by: End-Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Home Care Centres
        • 5.2.3.3. Pharmacies
        • 5.2.3.4. Others
      • 5.2.4. Global Argatroban Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Singapore
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Spain
          • 5.2.4.3.7. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Saudi Arabia
          • 5.2.4.4.2. Turkey
          • 5.2.4.4.3. Israel
          • 5.2.4.4.4. United Arab Emirates
          • 5.2.4.4.5. South Africa
          • 5.2.4.4.6. Rest of Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Argatroban: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer, Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Caplin Point Laboratories Ltd (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Fresenius-Kabi (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eagle Pharmaceuticals, Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mitsubishi Tanabe Pharma (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. WEST-WARD,INC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Midas Pharma GmBH (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Aurobindo Pharma Limited (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Argatroban Sale, by Type, Application, End-Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Argatroban (Value)
      • 7.2.1. Global Argatroban by: Type (Value)
        • 7.2.1.1. Argatroban Powder
        • 7.2.1.2. Argatroban Injection
      • 7.2.2. Global Argatroban by: Application (Value)
        • 7.2.2.1. Heparin-induced Thrombocytopenia (HIT)
        • 7.2.2.2. Percutaneous Coronary Intervention
        • 7.2.2.3. Cerebral Arterial Thrombosis
        • 7.2.2.4. Others
      • 7.2.3. Global Argatroban by: End-Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Home Care Centres
        • 7.2.3.3. Pharmacies
        • 7.2.3.4. Others
      • 7.2.4. Global Argatroban Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Singapore
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Spain
          • 7.2.4.3.7. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Saudi Arabia
          • 7.2.4.4.2. Turkey
          • 7.2.4.4.3. Israel
          • 7.2.4.4.4. United Arab Emirates
          • 7.2.4.4.5. South Africa
          • 7.2.4.4.6. Rest of Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Argatroban: by Type(USD Million)
  • Table 2. Argatroban Argatroban Powder , by Region USD Million (2015-2020)
  • Table 3. Argatroban Argatroban Injection , by Region USD Million (2015-2020)
  • Table 4. Argatroban: by Application(USD Million)
  • Table 5. Argatroban Heparin-induced Thrombocytopenia (HIT) , by Region USD Million (2015-2020)
  • Table 6. Argatroban Percutaneous Coronary Intervention , by Region USD Million (2015-2020)
  • Table 7. Argatroban Cerebral Arterial Thrombosis , by Region USD Million (2015-2020)
  • Table 8. Argatroban Others , by Region USD Million (2015-2020)
  • Table 9. Argatroban: by End-Use(USD Million)
  • Table 10. Argatroban Hospitals , by Region USD Million (2015-2020)
  • Table 11. Argatroban Home Care Centres , by Region USD Million (2015-2020)
  • Table 12. Argatroban Pharmacies , by Region USD Million (2015-2020)
  • Table 13. Argatroban Others , by Region USD Million (2015-2020)
  • Table 14. South America Argatroban, by Country USD Million (2015-2020)
  • Table 15. South America Argatroban, by Type USD Million (2015-2020)
  • Table 16. South America Argatroban, by Application USD Million (2015-2020)
  • Table 17. South America Argatroban, by End-Use USD Million (2015-2020)
  • Table 18. Brazil Argatroban, by Type USD Million (2015-2020)
  • Table 19. Brazil Argatroban, by Application USD Million (2015-2020)
  • Table 20. Brazil Argatroban, by End-Use USD Million (2015-2020)
  • Table 21. Argentina Argatroban, by Type USD Million (2015-2020)
  • Table 22. Argentina Argatroban, by Application USD Million (2015-2020)
  • Table 23. Argentina Argatroban, by End-Use USD Million (2015-2020)
  • Table 24. Rest of South America Argatroban, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Argatroban, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Argatroban, by End-Use USD Million (2015-2020)
  • Table 27. Asia Pacific Argatroban, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Argatroban, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Argatroban, by Application USD Million (2015-2020)
  • Table 30. Asia Pacific Argatroban, by End-Use USD Million (2015-2020)
  • Table 31. China Argatroban, by Type USD Million (2015-2020)
  • Table 32. China Argatroban, by Application USD Million (2015-2020)
  • Table 33. China Argatroban, by End-Use USD Million (2015-2020)
  • Table 34. Japan Argatroban, by Type USD Million (2015-2020)
  • Table 35. Japan Argatroban, by Application USD Million (2015-2020)
  • Table 36. Japan Argatroban, by End-Use USD Million (2015-2020)
  • Table 37. India Argatroban, by Type USD Million (2015-2020)
  • Table 38. India Argatroban, by Application USD Million (2015-2020)
  • Table 39. India Argatroban, by End-Use USD Million (2015-2020)
  • Table 40. South Korea Argatroban, by Type USD Million (2015-2020)
  • Table 41. South Korea Argatroban, by Application USD Million (2015-2020)
  • Table 42. South Korea Argatroban, by End-Use USD Million (2015-2020)
  • Table 43. Singapore Argatroban, by Type USD Million (2015-2020)
  • Table 44. Singapore Argatroban, by Application USD Million (2015-2020)
  • Table 45. Singapore Argatroban, by End-Use USD Million (2015-2020)
  • Table 46. Australia Argatroban, by Type USD Million (2015-2020)
  • Table 47. Australia Argatroban, by Application USD Million (2015-2020)
  • Table 48. Australia Argatroban, by End-Use USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Argatroban, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Argatroban, by Application USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Argatroban, by End-Use USD Million (2015-2020)
  • Table 52. Europe Argatroban, by Country USD Million (2015-2020)
  • Table 53. Europe Argatroban, by Type USD Million (2015-2020)
  • Table 54. Europe Argatroban, by Application USD Million (2015-2020)
  • Table 55. Europe Argatroban, by End-Use USD Million (2015-2020)
  • Table 56. Germany Argatroban, by Type USD Million (2015-2020)
  • Table 57. Germany Argatroban, by Application USD Million (2015-2020)
  • Table 58. Germany Argatroban, by End-Use USD Million (2015-2020)
  • Table 59. France Argatroban, by Type USD Million (2015-2020)
  • Table 60. France Argatroban, by Application USD Million (2015-2020)
  • Table 61. France Argatroban, by End-Use USD Million (2015-2020)
  • Table 62. Italy Argatroban, by Type USD Million (2015-2020)
  • Table 63. Italy Argatroban, by Application USD Million (2015-2020)
  • Table 64. Italy Argatroban, by End-Use USD Million (2015-2020)
  • Table 65. United Kingdom Argatroban, by Type USD Million (2015-2020)
  • Table 66. United Kingdom Argatroban, by Application USD Million (2015-2020)
  • Table 67. United Kingdom Argatroban, by End-Use USD Million (2015-2020)
  • Table 68. Netherlands Argatroban, by Type USD Million (2015-2020)
  • Table 69. Netherlands Argatroban, by Application USD Million (2015-2020)
  • Table 70. Netherlands Argatroban, by End-Use USD Million (2015-2020)
  • Table 71. Spain Argatroban, by Type USD Million (2015-2020)
  • Table 72. Spain Argatroban, by Application USD Million (2015-2020)
  • Table 73. Spain Argatroban, by End-Use USD Million (2015-2020)
  • Table 74. Rest of Europe Argatroban, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Argatroban, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Argatroban, by End-Use USD Million (2015-2020)
  • Table 77. MEA Argatroban, by Country USD Million (2015-2020)
  • Table 78. MEA Argatroban, by Type USD Million (2015-2020)
  • Table 79. MEA Argatroban, by Application USD Million (2015-2020)
  • Table 80. MEA Argatroban, by End-Use USD Million (2015-2020)
  • Table 81. Saudi Arabia Argatroban, by Type USD Million (2015-2020)
  • Table 82. Saudi Arabia Argatroban, by Application USD Million (2015-2020)
  • Table 83. Saudi Arabia Argatroban, by End-Use USD Million (2015-2020)
  • Table 84. Turkey Argatroban, by Type USD Million (2015-2020)
  • Table 85. Turkey Argatroban, by Application USD Million (2015-2020)
  • Table 86. Turkey Argatroban, by End-Use USD Million (2015-2020)
  • Table 87. Israel Argatroban, by Type USD Million (2015-2020)
  • Table 88. Israel Argatroban, by Application USD Million (2015-2020)
  • Table 89. Israel Argatroban, by End-Use USD Million (2015-2020)
  • Table 90. United Arab Emirates Argatroban, by Type USD Million (2015-2020)
  • Table 91. United Arab Emirates Argatroban, by Application USD Million (2015-2020)
  • Table 92. United Arab Emirates Argatroban, by End-Use USD Million (2015-2020)
  • Table 93. South Africa Argatroban, by Type USD Million (2015-2020)
  • Table 94. South Africa Argatroban, by Application USD Million (2015-2020)
  • Table 95. South Africa Argatroban, by End-Use USD Million (2015-2020)
  • Table 96. Rest of Africa Argatroban, by Type USD Million (2015-2020)
  • Table 97. Rest of Africa Argatroban, by Application USD Million (2015-2020)
  • Table 98. Rest of Africa Argatroban, by End-Use USD Million (2015-2020)
  • Table 99. North America Argatroban, by Country USD Million (2015-2020)
  • Table 100. North America Argatroban, by Type USD Million (2015-2020)
  • Table 101. North America Argatroban, by Application USD Million (2015-2020)
  • Table 102. North America Argatroban, by End-Use USD Million (2015-2020)
  • Table 103. United States Argatroban, by Type USD Million (2015-2020)
  • Table 104. United States Argatroban, by Application USD Million (2015-2020)
  • Table 105. United States Argatroban, by End-Use USD Million (2015-2020)
  • Table 106. Canada Argatroban, by Type USD Million (2015-2020)
  • Table 107. Canada Argatroban, by Application USD Million (2015-2020)
  • Table 108. Canada Argatroban, by End-Use USD Million (2015-2020)
  • Table 109. Mexico Argatroban, by Type USD Million (2015-2020)
  • Table 110. Mexico Argatroban, by Application USD Million (2015-2020)
  • Table 111. Mexico Argatroban, by End-Use USD Million (2015-2020)
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Argatroban: by Type(USD Million)
  • Table 124. Argatroban Argatroban Powder , by Region USD Million (2021-2026)
  • Table 125. Argatroban Argatroban Injection , by Region USD Million (2021-2026)
  • Table 126. Argatroban: by Application(USD Million)
  • Table 127. Argatroban Heparin-induced Thrombocytopenia (HIT) , by Region USD Million (2021-2026)
  • Table 128. Argatroban Percutaneous Coronary Intervention , by Region USD Million (2021-2026)
  • Table 129. Argatroban Cerebral Arterial Thrombosis , by Region USD Million (2021-2026)
  • Table 130. Argatroban Others , by Region USD Million (2021-2026)
  • Table 131. Argatroban: by End-Use(USD Million)
  • Table 132. Argatroban Hospitals , by Region USD Million (2021-2026)
  • Table 133. Argatroban Home Care Centres , by Region USD Million (2021-2026)
  • Table 134. Argatroban Pharmacies , by Region USD Million (2021-2026)
  • Table 135. Argatroban Others , by Region USD Million (2021-2026)
  • Table 136. South America Argatroban, by Country USD Million (2021-2026)
  • Table 137. South America Argatroban, by Type USD Million (2021-2026)
  • Table 138. South America Argatroban, by Application USD Million (2021-2026)
  • Table 139. South America Argatroban, by End-Use USD Million (2021-2026)
  • Table 140. Brazil Argatroban, by Type USD Million (2021-2026)
  • Table 141. Brazil Argatroban, by Application USD Million (2021-2026)
  • Table 142. Brazil Argatroban, by End-Use USD Million (2021-2026)
  • Table 143. Argentina Argatroban, by Type USD Million (2021-2026)
  • Table 144. Argentina Argatroban, by Application USD Million (2021-2026)
  • Table 145. Argentina Argatroban, by End-Use USD Million (2021-2026)
  • Table 146. Rest of South America Argatroban, by Type USD Million (2021-2026)
  • Table 147. Rest of South America Argatroban, by Application USD Million (2021-2026)
  • Table 148. Rest of South America Argatroban, by End-Use USD Million (2021-2026)
  • Table 149. Asia Pacific Argatroban, by Country USD Million (2021-2026)
  • Table 150. Asia Pacific Argatroban, by Type USD Million (2021-2026)
  • Table 151. Asia Pacific Argatroban, by Application USD Million (2021-2026)
  • Table 152. Asia Pacific Argatroban, by End-Use USD Million (2021-2026)
  • Table 153. China Argatroban, by Type USD Million (2021-2026)
  • Table 154. China Argatroban, by Application USD Million (2021-2026)
  • Table 155. China Argatroban, by End-Use USD Million (2021-2026)
  • Table 156. Japan Argatroban, by Type USD Million (2021-2026)
  • Table 157. Japan Argatroban, by Application USD Million (2021-2026)
  • Table 158. Japan Argatroban, by End-Use USD Million (2021-2026)
  • Table 159. India Argatroban, by Type USD Million (2021-2026)
  • Table 160. India Argatroban, by Application USD Million (2021-2026)
  • Table 161. India Argatroban, by End-Use USD Million (2021-2026)
  • Table 162. South Korea Argatroban, by Type USD Million (2021-2026)
  • Table 163. South Korea Argatroban, by Application USD Million (2021-2026)
  • Table 164. South Korea Argatroban, by End-Use USD Million (2021-2026)
  • Table 165. Singapore Argatroban, by Type USD Million (2021-2026)
  • Table 166. Singapore Argatroban, by Application USD Million (2021-2026)
  • Table 167. Singapore Argatroban, by End-Use USD Million (2021-2026)
  • Table 168. Australia Argatroban, by Type USD Million (2021-2026)
  • Table 169. Australia Argatroban, by Application USD Million (2021-2026)
  • Table 170. Australia Argatroban, by End-Use USD Million (2021-2026)
  • Table 171. Rest of Asia-Pacific Argatroban, by Type USD Million (2021-2026)
  • Table 172. Rest of Asia-Pacific Argatroban, by Application USD Million (2021-2026)
  • Table 173. Rest of Asia-Pacific Argatroban, by End-Use USD Million (2021-2026)
  • Table 174. Europe Argatroban, by Country USD Million (2021-2026)
  • Table 175. Europe Argatroban, by Type USD Million (2021-2026)
  • Table 176. Europe Argatroban, by Application USD Million (2021-2026)
  • Table 177. Europe Argatroban, by End-Use USD Million (2021-2026)
  • Table 178. Germany Argatroban, by Type USD Million (2021-2026)
  • Table 179. Germany Argatroban, by Application USD Million (2021-2026)
  • Table 180. Germany Argatroban, by End-Use USD Million (2021-2026)
  • Table 181. France Argatroban, by Type USD Million (2021-2026)
  • Table 182. France Argatroban, by Application USD Million (2021-2026)
  • Table 183. France Argatroban, by End-Use USD Million (2021-2026)
  • Table 184. Italy Argatroban, by Type USD Million (2021-2026)
  • Table 185. Italy Argatroban, by Application USD Million (2021-2026)
  • Table 186. Italy Argatroban, by End-Use USD Million (2021-2026)
  • Table 187. United Kingdom Argatroban, by Type USD Million (2021-2026)
  • Table 188. United Kingdom Argatroban, by Application USD Million (2021-2026)
  • Table 189. United Kingdom Argatroban, by End-Use USD Million (2021-2026)
  • Table 190. Netherlands Argatroban, by Type USD Million (2021-2026)
  • Table 191. Netherlands Argatroban, by Application USD Million (2021-2026)
  • Table 192. Netherlands Argatroban, by End-Use USD Million (2021-2026)
  • Table 193. Spain Argatroban, by Type USD Million (2021-2026)
  • Table 194. Spain Argatroban, by Application USD Million (2021-2026)
  • Table 195. Spain Argatroban, by End-Use USD Million (2021-2026)
  • Table 196. Rest of Europe Argatroban, by Type USD Million (2021-2026)
  • Table 197. Rest of Europe Argatroban, by Application USD Million (2021-2026)
  • Table 198. Rest of Europe Argatroban, by End-Use USD Million (2021-2026)
  • Table 199. MEA Argatroban, by Country USD Million (2021-2026)
  • Table 200. MEA Argatroban, by Type USD Million (2021-2026)
  • Table 201. MEA Argatroban, by Application USD Million (2021-2026)
  • Table 202. MEA Argatroban, by End-Use USD Million (2021-2026)
  • Table 203. Saudi Arabia Argatroban, by Type USD Million (2021-2026)
  • Table 204. Saudi Arabia Argatroban, by Application USD Million (2021-2026)
  • Table 205. Saudi Arabia Argatroban, by End-Use USD Million (2021-2026)
  • Table 206. Turkey Argatroban, by Type USD Million (2021-2026)
  • Table 207. Turkey Argatroban, by Application USD Million (2021-2026)
  • Table 208. Turkey Argatroban, by End-Use USD Million (2021-2026)
  • Table 209. Israel Argatroban, by Type USD Million (2021-2026)
  • Table 210. Israel Argatroban, by Application USD Million (2021-2026)
  • Table 211. Israel Argatroban, by End-Use USD Million (2021-2026)
  • Table 212. United Arab Emirates Argatroban, by Type USD Million (2021-2026)
  • Table 213. United Arab Emirates Argatroban, by Application USD Million (2021-2026)
  • Table 214. United Arab Emirates Argatroban, by End-Use USD Million (2021-2026)
  • Table 215. South Africa Argatroban, by Type USD Million (2021-2026)
  • Table 216. South Africa Argatroban, by Application USD Million (2021-2026)
  • Table 217. South Africa Argatroban, by End-Use USD Million (2021-2026)
  • Table 218. Rest of Africa Argatroban, by Type USD Million (2021-2026)
  • Table 219. Rest of Africa Argatroban, by Application USD Million (2021-2026)
  • Table 220. Rest of Africa Argatroban, by End-Use USD Million (2021-2026)
  • Table 221. North America Argatroban, by Country USD Million (2021-2026)
  • Table 222. North America Argatroban, by Type USD Million (2021-2026)
  • Table 223. North America Argatroban, by Application USD Million (2021-2026)
  • Table 224. North America Argatroban, by End-Use USD Million (2021-2026)
  • Table 225. United States Argatroban, by Type USD Million (2021-2026)
  • Table 226. United States Argatroban, by Application USD Million (2021-2026)
  • Table 227. United States Argatroban, by End-Use USD Million (2021-2026)
  • Table 228. Canada Argatroban, by Type USD Million (2021-2026)
  • Table 229. Canada Argatroban, by Application USD Million (2021-2026)
  • Table 230. Canada Argatroban, by End-Use USD Million (2021-2026)
  • Table 231. Mexico Argatroban, by Type USD Million (2021-2026)
  • Table 232. Mexico Argatroban, by Application USD Million (2021-2026)
  • Table 233. Mexico Argatroban, by End-Use USD Million (2021-2026)
  • Table 234. Research Programs/Design for This Report
  • Table 235. Key Data Information from Secondary Sources
  • Table 236. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Argatroban: by Type USD Million (2015-2020)
  • Figure 5. Global Argatroban: by Application USD Million (2015-2020)
  • Figure 6. Global Argatroban: by End-Use USD Million (2015-2020)
  • Figure 7. South America Argatroban Share (%), by Country
  • Figure 8. Asia Pacific Argatroban Share (%), by Country
  • Figure 9. Europe Argatroban Share (%), by Country
  • Figure 10. MEA Argatroban Share (%), by Country
  • Figure 11. North America Argatroban Share (%), by Country
  • Figure 12. Global Argatroban share by Players 2020 (%)
  • Figure 13. Global Argatroban share by Players (Top 3) 2020(%)
  • Figure 14. Global Argatroban share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Pfizer, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 17. Pfizer, Inc (United States) Revenue: by Geography 2020
  • Figure 18. Caplin Point Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 19. Caplin Point Laboratories Ltd (India) Revenue: by Geography 2020
  • Figure 20. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 22. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 24. Fresenius-Kabi (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Fresenius-Kabi (Germany) Revenue: by Geography 2020
  • Figure 26. Eagle Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 27. Eagle Pharmaceuticals, Inc (United States) Revenue: by Geography 2020
  • Figure 28. Mitsubishi Tanabe Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Mitsubishi Tanabe Pharma (Japan) Revenue: by Geography 2020
  • Figure 30. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 31. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2020
  • Figure 32. WEST-WARD,INC (United States) Revenue, Net Income and Gross profit
  • Figure 33. WEST-WARD,INC (United States) Revenue: by Geography 2020
  • Figure 34. Midas Pharma GmBH (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Midas Pharma GmBH (Germany) Revenue: by Geography 2020
  • Figure 36. Aurobindo Pharma Limited (India) Revenue, Net Income and Gross profit
  • Figure 37. Aurobindo Pharma Limited (India) Revenue: by Geography 2020
  • Figure 38. Global Argatroban: by Type USD Million (2021-2026)
  • Figure 39. Global Argatroban: by Application USD Million (2021-2026)
  • Figure 40. Global Argatroban: by End-Use USD Million (2021-2026)
  • Figure 41. South America Argatroban Share (%), by Country
  • Figure 42. Asia Pacific Argatroban Share (%), by Country
  • Figure 43. Europe Argatroban Share (%), by Country
  • Figure 44. MEA Argatroban Share (%), by Country
  • Figure 45. North America Argatroban Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer, Inc (United States)
  • Caplin Point Laboratories Ltd (India)
  • Novartis (Switzerland)
  • GlaxoSmithKline Plc (United Kingdom)
  • Fresenius-Kabi (Germany)
  • Eagle Pharmaceuticals, Inc (United States)
  • Mitsubishi Tanabe Pharma (Japan)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • WEST-WARD,INC (United States)
  • Midas Pharma GmBH (Germany)
  • Aurobindo Pharma Limited (India)
Select User Access Type

Key Highlights of Report


Jul 2021 236 Pages 87 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Argatroban Quantitative research analysis
Global Argatroban Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Argatroban market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Argatroban market are Pfizer, Inc (United States), Caplin Point Laboratories Ltd (India), Novartis (Switzerland), GlaxoSmithKline Plc (United Kingdom), Fresenius-Kabi (Germany), Eagle Pharmaceuticals, Inc (United States), Mitsubishi Tanabe Pharma (Japan), Teva Pharmaceutical Industries Ltd (Israel), WEST-WARD,INC (United States), Midas Pharma GmBH (Germany) and Aurobindo Pharma Limited (India), to name a few.
"Rising Incidence of Cerebral Arterial Thrombosis" is seen as one of major influencing trends for Argatroban Market during projected period 2020-2026.

Know More About Global Argatroban Report?

Have a Query? Click Here

Other Related Reports

Deferasirox Comprehensive Study by Type (Tablets, Suspension, Granules, Others), Application (Transfusional Iron Overload, Non-Transfusional Iron Overload, Others), Distribution Channel (Pharmacy Sto...
$ 3650
Varicella Vaccine Comprehensive Study by Type (Monovalent Varicella Vaccine, Combination Varicella Vaccine), Application (Pharmaceutical & Healthcare Products, Food & Beverages, Household & Personal ...
$ 3750
Biologics Comprehensive Study by Type (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, Other), Application (Cancer, Infectious Diseases...
$ 3800
Cancer Drug Therapy Comprehensive Study by Type (Targeted Therapy, Chemotherapy, Immunotherapy), Application (Angiogenesis Inhibitors, MTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (...
$ 3750
Internal Analgesic Tablet Comprehensive Study by Type (Central Painkiller, Narcotic Analgesics, Antispasmodic Painkillers, Anxiolytic Analgesics), Application (Home Use, Hospital, Clinic, Others), Di...
$ 3750
Essential Thrombocythemia Drug Comprehensive Study by Type (Givinostat, Idasanutlin, Pracinostat, Ruxolitinib Phosphate, Others), Application (Research Center, Hospital, Clinic, Others), Consumption ...
$ 3650